Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: pistachio  study  health  benefits  pregnant  women  food  nutrition  gdm  multivu  8162751  children  health  diabetes  novo  nordisk  heathcare  kids  insulin  type  1  treatment  multivu  7962351  health  medicine  company  chemicals  drugs  cancer  diabetes  disease  treatment  multivu  7809951  novo  nordisk  changing  diabetes  children  international  global  adolescent  diabetes  insulin  healthcare  multivu  7496851  novo  nordisk  changing  diabetes  children  international  global  adolescent  diabetes  insulin  healthcare  multivu  7496851  novo  nordisk  changing  diabetes  children  international  global  adolescent  diabetes  insulin  healthcare  multivu  7496851  diabetes  diabetic  blood  glucose  meter  glucose  accuchek  accucheck  aviva  expert  health  blood  sugar  insulin  healthcare  mult  novo  nordisk  ryzodeg  insulin  glycaemic  control  hypoglycaemia  type  2  diabetes  management  trial  study  multivu  64158  diabetes  technology  society  blood  sugar  level  glucose  monitor  patients  insulin  multivu  61870  novolog  community  star  contest  type  2  diabetes  management  insulin  patients  health  multivu  59947 
Search // insulin
Results 1-10 of 10 for ' insulin ' (0 seconds)
During the Academy of Nutrition and Dietetics 2017 Food & Nutrition Conference & Expo™ in Chicago, scientists reported on a recent study which uncovered that the intake of pistachios reduces the rise in blood sugar and insulin in women diagnosed with gestational diabetes mellitus (GDM)—commonly known as gestational diabetes. The study, “Effects of Pistachio Intake on Postprandial Blood Glucose Response in Pregnant Women,” found when women who were gestational glucose intolerant (GIGT) or who were diagnosed with GDM ate pistachios, they had a significantly lower rise in blood glucose levels compared to eating whole wheat bread that was matched for calories. To view the multimedia release go to: https://www.multivu.com/players/English/8162751-american-pistachio-growers-pistachio-health-benefits-women-gestational-diabetes/
Categories // Miscellaneous 
Added: 1706 days ago by MultiVuVideos
Runtime: 0m25s | Views: 365 | Comments: 2
Not yet rated
 

 

 

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme. Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care. To view the multimedia release go to: http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
Categories // Miscellaneous 
Added: 2049 days ago by MultiVuVideos
Runtime: 4m20s | Views: 343 | Comments: 0
Not yet rated
 

 

 

Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis. Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease. “As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.” To view the multimedia release go to: http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Categories // Miscellaneous 
Added: 2238 days ago by MultiVuVideos
Runtime: 2m30s | Views: 435 | Comments: 0
Not yet rated
 

 

 

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Categories // Miscellaneous 
Added: 2630 days ago by MultiVuVideos
Runtime: 7m15s | Views: 444 | Comments: 0
Not yet rated
 

 

 

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Categories // Miscellaneous 
Added: 2630 days ago by MultiVuVideos
Runtime: 5m9s | Views: 435 | Comments: 0
Not yet rated
 

 

 

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Categories // Miscellaneous 
Added: 2630 days ago by MultiVuVideos
Runtime: 2m6s | Views: 413 | Comments: 0
Not yet rated
 

 

 

ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Added: 2839 days ago by MultiVuVideos
Runtime: 0m30s | Views: 595 | Comments: 0
Not yet rated
 

 

 

Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1. Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Categories // Business  Science and Technology 
Added: 3126 days ago by MultiVuVideos
Runtime: 3m21s | Views: 575 | Comments: 1
Not yet rated
 

 

 

Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards. To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Added: 3316 days ago by MultiVuVideos
Runtime: 2m46s | Views: 1263 | Comments: 0
Not yet rated
 

 

 

Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities. Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management. To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
Categories // People and Blog 
Added: 3441 days ago by MultiVuVideos
Runtime: 4m2s | Views: 698 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2022 ClipMoon.com. All rights reserved.